Articles

Podcasts

Videos

Simon Walsh, MD, and Elizabeth Estes join Lungcast to discuss advancements in biomarker and treatment option deliberation for the rare disease through data.

How AI, Machine Learning Are Providing an Edge on Interstitial Lung Disease

A discussion on the recent success of phase 3 trials regarding chronic sinusitis and nasal polyp treatment.

James Palmer, MD, FARS: Chronic Rhinosinusitis And Phase 3 Trials For Treatment Device

Patients with pulmonary tuberculosis (TB) exhibited an improvement in quality of life and a reduction in treatment costs by utilizing a digital medication event reminder monitor (MERM).

Digital Medication Device Improves Quality of Life, Reduces Costs for TB Patients

For the second annual Interstitial Lung Disease Day, Dr. Briana DiSilvio expands on the background of ILDs and the latest care practices. 

Briana DiSilvio, MD, Shares Current Insights on Interstitial Lung Disease for ILD Day

Cases and hospitalizations due to EV-D68, a rare form of enterovirus associated with acute flaccid myelitis (AFM), have been increasing among children across the country.

CDC Alerts Pediatricians of Rare Respiratory Disease, Provides Recommendations

Respiratory symptoms are significant among individuals with a history of smoking tobacco even without airflow obstruction. 

Bronchodilator Therapy in Tobacco-Exposed Individuals Doesn't Relieve Symptoms

Novel insights into the risk-benefit profile of nintedanib in children and adolescents with fibrosing interstitial lung disease (ILD) were provided by late-breaking data presented at ERS 2022 regarding the InPedILD clinical trial.

Promising Data from InPedILD Phase 3 Trial Revealed at ERS Congress 2022

Late-breaking data presented at ERS Congress 2022 show that inhaler sensors and mobile health (mHealth) applications combined with pharmacist counseling improved treatment adherence for patients with uncontrolled asthma. 

Pharmacy-Supported Digital Medicine Program Improves Asthma Control

These data support web-based self-management for individuals with COPD with an objective, clinically relevant, short-term increase in physical activity levels compared to usual care.

ERS Data Support Web-Based Management to Increase Physical Activity in COPD Population

“From this study it makes sense that the (icenticaftor) 300mg dose has a benefit-risk profile to further study the clinical benefits,” Dr. Frits Franssen, lead investigator, said at ERS Congress 2022.

Phase 2b Study Supports Icenticaftor for Patients with COPD, Chronic Bronchitis

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Deep Vein Thrombosis 

The HCPLive deep vein thrombosis page is a resource for medical news and expert insights on DVT. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonology